Porton Pharma Solutions Ltd

Porton Pharma Solutions is a global Contract Development and Manufacturing Organisation (CDMO) that provides end-to-end services for pharmaceutical and biopharmaceutical development and manufacturing.

Founded in 2005, Porton Pharma Solutions has established itself as a trusted partner for pharmaceutical companies worldwide, offering comprehensive solutions spanning the entire drug lifecycle. The company operates through a robust platform that includes small molecules, biologics, conjugates, and advanced therapy medicinal products (ATMPs). With its headquarters in China and facilities across multiple regions, Porton ensures seamless project execution with a focus on quality, innovation, and regulatory compliance.

Porton's mission is to accelerate drug development and manufacturing timelines while maintaining cost efficiency and environmental sustainability. Their commitment to environmental, social, and governance (ESG) principles underscores their dedication to sustainable operations and corporate responsibility.

Key Products and Services:

• Small Molecules CDMO Services: Process development, optimisation, and commercial-scale manufacturing.
• Biologics and Conjugates: Including Antibody-Drug Conjugates (ADCs), Antibody-Oligonucleotide Conjugates (AOCs), Peptide-Drug Conjugates (PDCs), and more.
• Advanced Therapy Medicinal Products (ATMPs): Support for cell and gene therapy platforms.
• Specialised Technologies: Flow chemistry, biocatalysis, crystallisation, and prep-chromatography.
• Regulatory Support: Assistance with CMC filing and global regulatory requirements.
• Sustainability Initiatives: Integration of eco-friendly practices across operations.

Porton Pharma Solutions continues to expand its capabilities to meet the growing needs of the pharmaceutical and biopharmaceutical sectors. By leveraging cutting-edge technologies and fostering innovation, the company aims to remain at the forefront of the CDMO industry while upholding its commitment to quality, sustainability, and client success.